Jewish General Hospital

Researchers

• WFWilliam D Foulkes

Running trials

• Enrolling by invitation

  Parathyroid Adenoma Detection With Rubidium-82 Imaging

  NCT07099404· Matthieu Pelletier-Galarneau, MD MSc· Source

• Not yet recruiting

  18F-FDG PET/CT for Diagnosis of Diabetic Foot Osteomyelitis

  NCT07828691· Jewish General Hospital· Source

• Not yet recruiting

  Phase II Study of CAmizestrant in Resectable Endometrial Adenocarcinoma

  NCT07840443· Phase 2· University Health Network, Toronto· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

  NCT07541170· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)

  NCT07777263· Phase 3· Dr. Tamim Niazi· Source

• Recruiting

  A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

  NCT07680790· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  Decision Aid for Anticoagulation Duration After Unprovoked Venous Thromboembolism

  NCT07659106· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.

  NCT07483658· CHU de Quebec-Universite Laval· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Incyte Corporation· Source

• Recruiting

  Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

  NCT06654336· Phase 2· Ontario Clinical Oncology Group (OCOG)· Source

• Not yet recruiting

  Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy

  NCT07373535· Phase 2· Kyle Greenway· Source

• Recruiting

  Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment

  NCT07304154· Phase 1· Kite, A Gilead Company· Source

• Recruiting

  A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07287150· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

  NCT07194382· Phase 2· Avalyn Pharma Inc.· Source

• Not yet recruiting

  Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance

  NCT07386171· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Not yet recruiting

  FMT in Triple Negative Breast Cancer Guided by ctDNA

  NCT07292142· Phase 1/2· Jewish General Hospital· Source

• Recruiting

  A Study Looking at a New Nerve Surgery to Help Men Regain Erections After Prostate Cancer Surgery

  NCT07188064· Sir Mortimer B. Davis - Jewish General Hospital· Source

• Recruiting

  A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

  NCT07277231· Phase 3· BeOne Medicines· Source

• Recruiting

  Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

  NCT07094048· Phase 4· CHU de Quebec-Universite Laval· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Intravascular Ultrasound for Peripheral Artery Disease Revascularization

  NCT06979284· Hamilton Health Sciences Corporation· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

  NCT06948448· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

  NCT06880523· Phase 2· Canadian Cancer Trials Group· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  Helping Couples Communicate Better: Does This Help Persons With Type 2 Diabetes Respond Better to a Step Count Prescription?

  NCT07142512· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Pfizer· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Relay Therapeutics, Inc.· Source

• Recruiting

  Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06896916· Phase 1· AbbVie· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Recruiting

  AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  NCT07094113· Phase 1· Amgen· Source

• Active, not recruiting

  P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

  NCT06468033· Phase 3· PharmaEssentia· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)

  NCT06440694· Phase 3· Ottawa Hospital Research Institute· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

  NCT06863272· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Enrolling by invitation

  A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

  NCT07038447· Phase 1· Kite, A Gilead Company· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

  NCT06698458· Alpha Tau Medical LTD.· Source

• Recruiting

  A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  NCT06340568· Phase 3· BioNTech SE· Source

• Recruiting

  Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  NCT06787612· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  NCT06592924· Phase 3· Canadian Cancer Trials Group· Source

• Recruiting

  A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  NCT06952504· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  NCT06846671· Phase 3· BeOne Medicines· Source

Showing 50 of 211.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer16 recruiting
• Colorectal cancer10 recruiting
• Lung cancer8 recruiting
• Metastatic breast cancer7 recruiting
• Multiple myeloma7 recruiting
• Myeloproliferative neoplasms6 recruiting
• Ovarian cancer6 recruiting
• Triple-negative breast cancer6 recruiting
• Chronic lymphocytic leukaemia5 recruiting
• Deep vein thrombosis and pulmonary embolism5 recruiting
• Endometrial cancer5 recruiting
• Acute myeloid leukaemia4 recruiting
• Melanoma3 recruiting
• Pancreatic cancer3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Childhood cancers2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Myelodysplastic syndromes2 recruiting
• Asthma1 recruiting
• Bladder cancer1 recruiting
• Brain metastases1 recruiting
• Chronic kidney disease1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Coronary artery disease1 recruiting
• Depression1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diabetic foot ulcer1 recruiting
• Follicular lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Hodgkin lymphoma1 recruiting
• Hyperparathyroidism1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lupus (SLE)1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting
• Osteoarthritis1 recruiting
• Peripheral artery disease1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoma1 recruiting
• Stroke1 recruiting
• Type 2 diabetes1 recruiting

Closed trials

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Incyte Corporation· Source

• Completed

  Evaluating the Effect of Questionnaire Context on the Reporting of Somatic Items Among People With Systemic Sclerosis

  NCT06772896· Lady Davis Institute· Source

• Completed

  Novel Robotic Prostatectomy Technique for Early Urinary Continence

  NCT06237114· Sir Mortimer B. Davis - Jewish General Hospital· Source

• Recruiting

  A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

  NCT06150157· Phase 1· Janssen Research & Development, LLC· Source

• Terminated

  Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

  NCT05413915· Phase 3· Sarit Assouline· Source

• Completed

  Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

  NCT06036836· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

  NCT05665530· Phase 1· Prelude Therapeutics Incorporated· Source

• Completed

  A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer

  NCT05634499· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

  NCT05427370· Sunnybrook Health Sciences Centre· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

  NCT05646862· Phase 3· Hoffmann-La Roche· Source

• Terminated

  Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

  NCT05860296· Phase 1/2· SignalChem Lifesciences Corporation· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT05287113· Phase 2· Incyte Biosciences International Sàrl· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

  NCT05444972· AbbVie· Source

• Terminated

  FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

  NCT05432193· Phase 1· POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company· Source

• Completed

  A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer

  NCT05415215· Phase 3· Hoffmann-La Roche· Source

• Completed

  Effect of Venous Cannulation on the Incidence of Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass

  NCT04641611· Dr. Jean-Francois Morin· Source

• Completed

  Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma

  NCT05303493· Phase 1· Centre hospitalier de l'Université de Montréal (CHUM)· Source

• Completed

  FDG Digital PET/CT as First Line Investigation for Giant Cell Arteritis

  NCT05000138· Jewish General Hospital· Source

• Terminated

  A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

  NCT05171049· Phase 3· Anthos Therapeutics, Inc.· Source

• Completed

  A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis

  NCT05238675· Phase 2· Boehringer Ingelheim· Source

• Terminated

  Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

  NCT05275439· Phase 1· Shattuck Labs, Inc.· Source

• Completed

  A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

  NCT05326516· Phase 1· Syndax Pharmaceuticals· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Withdrawn

  Use of Chinese Herbal Formula Shu Yu Wan in Lung Cancer Patients

  NCT04615884· Lady Davis Institute· Source

• Completed

  A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

  NCT04896008· Phase 3· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Terminated

  Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

  NCT04794569· Phase 4· Sunnybrook Health Sciences Centre· Source

• Recruiting

  A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

  NCT04929223· Phase 1· Hoffmann-La Roche· Source

• Completed

  Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

  NCT05008224· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)

  NCT04246528· Lady Davis Institute· Source

• Completed

  An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network

  NCT04564079· Exactis Innovation· Source

• Recruiting

  Brexpiprazole Treatment for Bipolar I Depression

  NCT04569448· Phase 3· Douglas Mental Health University Institute· Source

• Terminated

  Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

  NCT04698915· Phase 2· Galera Therapeutics, Inc.· Source

• Completed

  INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

  NCT04455841· Phase 1/2· Incyte Corporation· Source

• Completed

  Contralesional Inhibitory rTMS for Recovery of Arm Function After Stroke

  NCT04205526· Thiel, Alexander, M.D.· Source

• Completed

  MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

  NCT04649359· Phase 2· Pfizer· Source

• Completed

  Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

  NCT04626518· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

  NCT04626479· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Terminated

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Phase 1/2· Ocellaris Pharma, Inc.· Source

• Completed

  Interactive Online Informational and Peer Support App for Patients with Low Anterior Resection Syndrome

  NCT04469426· Jewish General Hospital· Source

• Completed

  A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

  NCT04300647· Phase 2· Hoffmann-La Roche· Source

• Completed

  Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant

  NCT04224272· Phase 2· Jazz Pharmaceuticals· Source

• Completed

  A Novel mHealth Application Guided by an Optimization Algorithm for T1D Sensor-Augmented Insulin Injection Users

  NCT04123054· McGill University· Source

• Completed

  Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

  NCT04068181· Phase 2· Amgen· Source

• Completed

  SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors

  NCT02840149· Phase 3· Jewish General Hospital· Source

• Completed

  Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT03781063· Phase 2· Sermonix Pharmaceuticals Inc.· Source

• Completed

  Impact of a Patient-Centered Program for Low Anterior Resection Syndrome a Multicenter Randomized Controlled Trial

  NCT03828318· Jewish General Hospital· Source

• Completed

  I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

  NCT03939689· Phase 2· Progenics Pharmaceuticals, Inc.· Source

Showing 50 of 88.

Conditions

Diseases this institution publishes on or runs trials for.

• Systemic sclerosis (scleroderma)24 works · 5 trials
• Pulmonary arterial hypertension10 works · 2 trials
• Dermatomyositis and polymyositis (myositis)4 works · 1 trial
• Giant cell arteritis4 works · 1 trial
• Uterine fibroids3 works · 0 trials